Figure 1.

Experimental protocol for the effective evaluation of HSA–Trx, Trx, or Tamiflu® on influenza-induced ALI model mice. Either HSA–Trx or Trx was administrated intravenously (1.75 nmol/mouse) at 4 and 6 days after virus infection. Tamiflu® was administrated intraperitoneally (10 mg/kg/day, 2 times/day) for a total of 4 days, starting 2 days after the virus infection. The efficacy of therapeutic agents was evaluated with mice sacrificed at 8 days after virus infection.